Search

Novel Prebiotic Fiber as Targeted Dietary Management of Irritable Bowel Syndrome

Company: NUTRABIOTIX, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): The objective of this Phase II SBIR application is to test NTX-1 fiber in patients with constipation-predominant IBS (IBS-C) and determine if it can reduce symptoms, beneficially modify gut microbiota composition, and improve gut milieu in these patients. Our… more

Multi-Functional Guidewire for Peripheral Vasculature

Company: 3DT HOLDINGS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Over 8 million Americans have peripheral vascular disease (PAD). Percutaneous transluminal artery (PTA) treatment of severe PAD involves the use of balloons and stents, but delivery of these therapies is often suboptimal due to inaccuracies in angiographic… more

Portable device for monitoring water balance in elderly

Company: 3DT HOLDINGS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Transseptal (TS) access for left heart procedures is an important and rapidly growing space for diagnostics and therapy delivery with an expected total of over 10 million U.S. patients. In the U.S. and/or Europe, TS access procedures are used for atrial… more

A mechanism-based computational tool to optimize pulmonary drug delivery

Company: 3DT HOLDINGS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Coronary artery disease (CAD) is a national and worldwide epidemic that places the largest clinical and economic burden on the healthcare system of any disease condition. Patients with stable and acute coronary conditions are often treated with percutaneous… more

Expanding Precision Particle Fabrication Technology for the Widespread Control of

Company: ORBIS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): A critical need currently exists in the pharmaceutical market for microparticles that can accurately and effectively control the release of poorly water-soluble compounds. Although these poorly water-soluble drugs areprojected to have high clinical efficacy,… more

Supporting Health, Activities, Resources, and Education: The SHARE Program for ea

Company: FIT INTERACTIVE, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): The SHARE Program: Supporting Health, Activities, Resources, and Education is a seven-session early stage intervention for care dyads (the IWD and a family CG) that takes advantage of a time when the IWD can still discuss the diagnosis and plan for the future.… more

A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma

Company: TUNITAS THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): The overall goal of this phase 2 SBIR proposal is to position our novel biologic GE2 for human clinical trials in allergic disease though the completion of critical preclinical development research activities. GE2, a genetically engineered human fusion protein… more

Body Worn EMG Controlling of Assistive Robotic Arm for Stroke Rehabilitation

Company: CARE TEAM SOLUTIONS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: ABSTRACT Technological aids supporting medication management for chronically ill patients are proliferating, offered in electronic telehealth devices. Pill organizers, reminders, monitors, and usage communicators have enabled an array of home health aids to support users and caregivers in pill… more

IGF::OT::IGF Contract Award to Care Team Solutions, LLC: Using mHealth to Aid Opi

Company: CARE TEAM SOLUTIONS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: Opiate-agonist pharmacotherapy utilizing buprenorphine/naloxone is known to decrease illicit opiate use. However, poor medication management and misuse during self-managed opioid substitution therapy (OST) constrains efficacy, while aggrandizing relapse,hospitalizations and mortality. One of the… more

Novel Design of a Fast-On/Fast-Off Insulin Analog for Closed-Loop Systems

Company: MASSTECH, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION: Significant increase in the efficiency and speed of MS-based tissue imaging (IMS) performed at atmospheric conditions using high-resolution mass spectrometer will have a profound impact on method applications to the entire analytical field ofcharacterization of biomarkers in tissues.… more

Control of Arthritic Pain by Inhibition of TRPA1 Activity

Company: KORONIS BIOMEDICAL TECHNOLOGIES CORPORAT Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Koronis Biomedical Technologies (KBT) proposes a novel tool to test the integrity of implantable cardioverter- defibrillator (ICD) leads in-situ. Siilar to pacemakers, ICDs are surgically implanted just under the skin outside of the patient's rib cage. An… more

Novel Reagents and Methods for Rapid and High Throughput Detection of Aflatoxin C

Company: AGRI-ANALYSIS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): This SBIR grant application is in response to PA-11-335, from Lab to Marketplace: Tools for Biomedical and Behavioral Research. The intent of PA-11-335 is to help move useful technologies from non-commercial laboratories into the commercial marketplace by… more

Micro-technology Enhanced Pediatric Lens Capsulotomy Device

Company: MYNOSYS CELLULAR DEVICES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): We propose an innovative microtechnology-enhanced surgical device that solves a significant therapeutic bottleneck in the treatment of lens cataract in children. As the leading cause of childhood blindness, lens cataract interferes with the optical performance of… more

System for PCS Agencies to Monitor, Investigate and Respond to Elder Safety Risks

Company: ADVANCED GENOMIC TECHNOLOGY, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): This project aims to generate blood tests for: 1. mild cognitive impairment (MCI), and 2. conversion risk from MCI to full-blown Alzheimer's disease (AD). We have reported that systemic footprints, increases in key micro- RNA (miR) levels, are identifiable… more

Novel Manufacturing Processes for Tissue Engineered Vascular Grafts

Company: HUMACYTE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): This Phase IIB SBIR application is responsive to NHLBI RFA HL-13-016, NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood and Sleep Disorders and Diseases (R44) . This RFA solicits work on basic,… more

Imaging Software of Functional Connectivity MRI for Alzheimer's Disease

Company: BRAINSYMPHONICS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): This application, Imaging Software of Functional Connectivity MRI for Alzheimer's Disease , is written in response to (PA-11-134) Lab to Marketplace: Tools for Brain and Behavioral Research (SBIR [R43/R44]) . Alzheimer's disease (AD) is the most… more

Mobile Motivation for Health Promotion Among Adolescents

Company: BODIMOJO, INC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): This Phase II SBIR application proposes the development and testing of a theory-based health promotion mobile phone application, BodiMojo, for adolescents (ages 13-18). The product is designed to: (1) promote wellness,healthy eating and physical activity in… more

Stabilization of Analytes in Blood Cells and Plasma

Company: Biomatrica, Inc. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: Whole blood remains the cornerstone specimen type used in molecular analysis. Changes in the DNA, RNA, protein, peptide, metabolic, and blood cell analyte levels during pre-analytic specimen handling between collection and eventual molecular analysis impacts testing accuracy and delegitimizes any… more

Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling

Company: ADAPTIVE TCR CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling T-cell neoplasms are generally more aggressive and have poorer outcomes than comparable B-cell lymphomas. In addition, for many of these patients, prognosis following disease relapse is… more

Correlating TCR diversity to immune reconstitution after cord blood transplant

Company: ADAPTIVE TCR CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): Many patients requiring stem cell transplantation for hematological malignancies are unable to find a suitable HLA-matched sibling or unrelated donor. Transplants using stem cells from umbilical cord blood provide an alternative for these patients, allowing… more

SBIR TOPIC 315: DEVELOPMENT OF COMPANION DIAGNOSTICS: ENABLING PRECISION MEDICINE

Company: ADAPTIVE TCR CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: Immunotherapy has emerged as a promising method to treat several cancers. In 2012 the FDA approved a new immunotherapy agent, ipilimumab, for metastatic melanoma. Ipilimumab activates T-cells and globally increases the adaptive immune response and resultsin an enhanced response to the cancer. In a… more

Genetically-delivered Bevacizumab for Treatment of Wet Age-Related Macular Degene

Company: REGENX BIOSCIENCES, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): The goal of this Phase I SBIR is the pre-clinical development of a novel gene-based delivery system for bevacizumab (anti-VEGF antibody) to treat wet age-related macular degeneration (AMD). The premise is based on: (1)the demonstrated efficacy of monthly… more

IGF::OT::IGF Aerosolized Delivery of Anti-Tubercular Drugs

Company: PULMOKINE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: Develop an inexpensive, easy to use, aerosolized delivery system of a combination of anti-tubercular drugs that could be used for the treatment of multi-drug resistant tuberculosis (MDR TB ). PUBLIC HEALTH RELEVANCE

Relating GPCRs by biased ligands for enhanced therapeutic efficacy

Company: SEACHANGE PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Goals: The goal is to expand the known pharmacological relationships among arrestin and G protein biased ligands. Starting with the Gi-coupled dopamine D2 receptor (D2R), we will predict biased ligands, evaluatingour methods both retrospectively and via… more

A platform to predict side-effect targets for drugs

Company: SEACHANGE PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): Bioactive small molecules can act on multiple targets, and these off-target activities underlie many of the adverse reactions from which drugs suffer. The motivating idea of this proposal is that these Adverse Drug Reaction (ADR) targets may be predicted… more